NCT05253131 2026-02-11
Trial of Selumetinib and Bromodomain Inhibitor With Durvalumab for Sarcomas
University of Alabama at Birmingham
Phase 2 Not yet recruiting
Clinical Trials
5 trialsNCT06735820 2025-07-03
MEKMDM2
Children's National Research Institute
Phase 1/2 Not yet recruiting
NCT03433183 2023-12-26
SARC031: MEK Inhibitor Selumetinib (AZD6244) in Combination With the mTOR Inhibitor Sirolimus for Patients With Malignant Peripheral Nerve Sheath Tumors
Sarcoma Alliance for Research through Collaboration
Phase 2 Completed
NCT01752569 2019-02-20
SCART
Sheffield Teaching Hospitals NHS Foundation Trust
Phase 1/2 Terminated
NCT01206140 2015-10-05
Selumetinib With or Without Temsirolimus in Treating Patients With Metastatic, Recurrent, or Locally Advanced Soft Tissue Sarcoma That Cannot Be Removed By Surgery
National Cancer Institute (NCI)
Phase 2 Completed